4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)
4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)
4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)
PORTLAND, Maine, Aug. 13, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended June 30, 2024. Q2 2024 Highlights: Product sales increased 55% versus the comparable quarter in 2023.Product sales increased 82% versus the comparable six-month period in 2023.Product sales increased 48% from the previous trailing twelve-month period ended June 30, 2023. Management's Discussion:"Our preliminary, unaudited
PORTLAND, Maine, Aug. 07, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended June 30, 2024 after the market closes on Tuesday, August 13, 2024. The Company is planning to host a conference call the next morning, Wednesday, August 14, 2024, at 9:00 AM ET to review the unaudited financial results. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (
PORTLAND, Maine, July 09, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the second quarter of 2024, which ended June 30, 2024. Preliminary, Unaudited Total Sales Results: 2024 2023 $ Increase % Increase During the Three-Month Periods Ended June 30,$5.47 million$3.53 million$1.94 million55% During the Six-Month Periods Ended June 30,$12.73 million$6.98 million$5.75 million82% During the Twe
PORTLAND, Maine, June 21, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that Bryan K. Gathagan has been appointed to its Board of Directors. Mr. Gathagan is the owner and a managing member of broad Thinking, LLC, a management consulting firm and has 25 years of animal health experience. He is a founding member of Animalytix LLC and has served as its Chief Financial and Chief Technology Officer since it began operations in 2010. Prior to Animalytix
SC 13D - IMMUCELL CORP /DE/ (0000811641) (Subject)
SC 13D/A - IMMUCELL CORP /DE/ (0000811641) (Subject)
SC 13G/A - IMMUCELL CORP /DE/ (0000811641) (Subject)
PORTLAND, Maine, Aug. 13, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended June 30, 2024. Q2 2024 Highlights: Product sales increased 55% versus the comparable quarter in 2023.Product sales increased 82% versus the comparable six-month period in 2023.Product sales increased 48% from the previous trailing twelve-month period ended June 30, 2023. Management's Discussion:"Our preliminary, unaudited
PORTLAND, Maine, Aug. 07, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended June 30, 2024 after the market closes on Tuesday, August 13, 2024. The Company is planning to host a conference call the next morning, Wednesday, August 14, 2024, at 9:00 AM ET to review the unaudited financial results. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (
PORTLAND, Maine, July 09, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the second quarter of 2024, which ended June 30, 2024. Preliminary, Unaudited Total Sales Results: 2024 2023 $ Increase % Increase During the Three-Month Periods Ended June 30,$5.47 million$3.53 million$1.94 million55% During the Six-Month Periods Ended June 30,$12.73 million$6.98 million$5.75 million82% During the Twe
10-Q - IMMUCELL CORP /DE/ (0000811641) (Filer)
8-K - IMMUCELL CORP /DE/ (0000811641) (Filer)
8-K - IMMUCELL CORP /DE/ (0000811641) (Filer)
With U.S. stock futures trading mixed this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Manchester United Plc. (NYSE:MANU) to report a quarterly loss at 27 cents per share on revenue of $162.92 million before the opening bell, according to data from Benzinga Pro. Manchester United shares gained 1.6% to $16.19 in the after-hours trading session. Kura Sushi USA (NASDAQ:KRUS) posted downbeat results for its third quarter on Tuesday. Kura Sushi shares fell 4.2% to $56.00 in the after-hours trading session. Analysts are expecting PriceSmart, Inc. (NASDAQ:PSMT) to post quarterly earnings at $1.01 per share on revenue of $